CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | pCODR 10178 |
|---|---|
| Brand Name | TBD |
| Generic Name | Bevacizumab |
| Strength | |
| Tumour Type | Gastrointestinal / Lung |
| Indication | Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer Biosimilar |
| Funding Request | Metastatic Colorectal Cancer (mCRC); Non-Small Cell Lung Cancer (NSCLC) |
| Review Status | File Closed |
| Pre Noc Submission | Yes |
| NOC Date | |
| Manufacturer | Pfizer Canada Inc. |
| Sponsor | Pfizer Canada Inc. |
| Submission Date | March 14, 2019 |
| Submission Date (Target Date) | |
| Submission Deemed Complete | March 28, 2019 |
| Submission Type | Biosimilar – New Drug |
| Stakeholder Input Deadline ‡ | March 28, 2019 |
| Final Biosimilar Summary Dossier Issued (target date) |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.